When should I take sleep gummies?

Quick answerMost people take sleep gummies 30–60 minutes before bedtime. Start with the labeled serving, take them at the same time nightly, and adjust timing to your routine. Educational content only—consult your clinician.When to useWhen winding down for the night (about 30–60 minutes pre-bed).When establishing a consistent nightly routine (same time every evening).How to useRead the label and COA to understand ingredients and serving size. Take the suggested serving 30–60 minutes before bed. Adjust timing by ±15 minutes as you learn your response; avoid alcohol near bedtime for best routine hygiene.SafetyGeneral information only; consult your clinician for personal advice.Avoid alcohol or other sedatives near bedtime.If you experience next-day grogginess or take medications, stop and speak with a healthcare professional.

Can I travel with CBD or THCV?

Policies depend on origin, destination, and carrier. Many domestic travelers carry hemp-derived CBD, but rules vary and change. Keep products in original packaging, carry the COA, follow liquids limits, and avoid international travel with cannabinoids unless legality is clearly verified. For THCV state-by-state context, see our legality map. General information only—consult your clinician.When to useWhen planning a domestic trip and considering hemp-derived CBD.When deciding whether to pack THCV or any THC-containing product.How to useBefore you go, check destination laws, your airline’s policy, and TSA or relevant authority guidance. Keep items sealed in original packaging with a copy of the COA; follow carry-on liquids rules and use checked baggage if your airline requires it.SafetyGeneral information only; verify with your airline and authorities.THC/THCV may be restricted; some jurisdictions have zero-tolerance policies.If prohibited at either end, do not carry; penalties can be severe.

Swiss Vitalis · International Patients Information

§ I International information

Edition · MMXXVI

Swiss Vitalis LLC · Newark, DE · USA

Hemp-derived CBD Made in the USA Informational page

Swiss Vitalis.
U.S.-made CBD,
for international
patients.

Information for international patients. Swiss Vitalis is a U.S.-based manufacturer of hemp-derived CBD products. This page provides general information for patients abroad — including those in Brazil — who wish to learn about our composition and manufacturing standards.

Read the information → View lab results (COA)

Manufactured in the USA

Hemp-derived · THC < 0.3%

Third-party lab tested

laboratory · USA

Rec · MMXXVI

Third-party
tested, per batch.

Vol · 01

U.S. manufacturing

2018 Farm Bill

Lab testing

COA per batch

Hemp-derived CBD manufactured in the United States Less than 0.3% THC under the 2018 U.S. Farm Bill Third-party lab testing certificates of analysis per batch Informational page for international patients No direct sales to Brazil informational content only Individual import patient responsibility under RDC 660/2022 Hemp-derived CBD manufactured in the United States Less than 0.3% THC under the 2018 U.S. Farm Bill Third-party lab testing certificates of analysis per batch Informational page for international patients

§ II About our products

Hemp-derived CBD,
manufactured in
the United States.

U.S.-made hemp-derived CBD products, with independent third-party testing and Certificates of Analysis issued at the batch level.

II.a · Product standards i.

About our products

Swiss Vitalis manufactures hemp-derived CBD products in the United States in compliance with applicable U.S. federal regulations, including the 2018 Farm Bill.

Our products contain less than 0.3% Δ9-THC by dry weight. Batch-level Certificates of Analysis (COAs) from independent, ISO-accredited third-party laboratories are published on our Lab Results page and updated as new lots are released.

Origin

United States

Framework

Farm Bill 2018

THC limit

< 0.3% dry wt.

Testing

Per batch

Manufactured in the USA Hemp-derived · less than 0.3% THC Independent third-party testing Batch-level traceability

View Certificates of Analysis swissvitalisusa.com

§ III International access

How international patients
access our products.

Swiss Vitalis does not ship directly to Brazil and does not operate a sales network in Brazil. The section below explains how the individual personal-import pathway works.

III.a · Individual import pathway ii.

How international patients access our products

We sell our products to customers located in the United States through our online store. We do not ship directly to Brazil.

Patients located in Brazil who wish to import cannabis-derived products for personal use must obtain an individual import authorization (Anuência de Importação) from ANVISA under RDC 660/2022, based on a valid prescription issued by a licensed Brazilian physician. The patient is the importer of record in any such transaction.

Swiss Vitalis is not involved in the authorization process and does not provide medical, regulatory, or legal advice. Patients are encouraged to consult their physician and, if desired, an independent import-assistance service of their own choosing.

U.S.-side fulfillment of shipments to international patients — including Brazilian patients who have individually obtained an Anuência de Importação from ANVISA under RDC 660/2022 — is handled by Novus Byzantium LLC, a Wyoming limited liability company and authorized U.S. distributor of Swiss Vitalis hemp-derived CBD products. Novus Byzantium LLC operates independently of Swiss Vitalis LLC, is not a Brazilian entity, does not operate commercially in Brazil, and does not replace the patient's role as the importer of record on any shipment.

III.b · ANVISA reference listing iii.

ANVISA reference listing

Swiss Vitalis CBD (Swiss Vitalis LLC, United States, 30 mL / 900–5000 mg) is included in ANVISA's published reference of cannabis-derived products eligible for the individual personal-import procedure under RDC 660/2022, Art. 5º §3º.

Reference document

Nota Técnica nº 19/2026/SEI/COCIC/GPCON/DIRE5/ANVISA

Annex

I

Dated

7 April 2026

Process

25351.927642/2021-31

SEI doc.

4174207

Patients located in Brazil who hold a valid prescription issued by a licensed Brazilian physician may apply directly to ANVISA, through the Federal Government Services Portal, for individual import authorization (Anuência de Importação) for personal use, in accordance with the procedure established by RDC 660/2022.

Important — ANVISA statement

ANVISA expressly states in the same Nota Técnica that products listed in this reference do not hold ANVISA approval and have not had their efficacy, quality or safety evaluated by the Agency. Inclusion in the reference does not constitute registration, approval, endorsement, recommendation, or commercial authorization. ANVISA further states that these products may not be imported, stored, distributed, or resold by legal entities in Brazil and must be imported exclusively by the natural-person patient for strictly personal, non-transferable use under Art. 15 of RDC 660/2022. Swiss Vitalis makes no therapeutic, diagnostic, curative, or preventive claim regarding any product.

View ANVISA reference document (Nota Técnica nº 19/2026) gov.br/anvisa

§ IV Regulatory notes

Regulatory and
legal notes.

Jurisdiction, responsibility, and the scope of the information provided on this page.

IV.a · Legal notes iv.

Regulatory and legal notes

Swiss Vitalis CBD is included in ANVISA's published reference of products eligible for the individual personal-import procedure under RDC 660/2022 (Nota Técnica nº 19/2026, Annex I).

Scope of inclusion

Inclusion in ANVISA's reference does not constitute ANVISA registration, commercial authorization, or approval. ANVISA expressly states that listed products have not had their efficacy, quality or safety evaluated, and that they may not be imported, stored, distributed, or resold by legal entities in Brazil.

Swiss Vitalis products are manufactured and sold in the United States. No representation is made that any product is registered, approved, or authorized by ANVISA, the FDA, or any other regulatory authority for the treatment, diagnosis, cure, or prevention of any disease.

Swiss Vitalis LLC (Delaware, USA) is the manufacturer of the product; Novus Byzantium LLC (Wyoming, USA) is the authorized U.S. distributor that handles outbound fulfillment to international personal-import patients. Neither entity is registered with ANVISA, and neither entity operates commercially in Brazil.

Any import of our products into Brazil by an individual patient is the sole responsibility of that patient and must comply with Brazilian law, including RDC 660/2022 and any applicable ANVISA requirements.

Swiss Vitalis does not solicit sales, maintain distributors, or advertise to the Brazilian public. Inquiries from international patients are answered on an informational basis only.

Contact Information

Swiss Vitalis LLC
254 Chapman Rd, Ste 208 #15869, Newark, Delaware 19702
United States

Phone: (302) 496-5448
Email: [email protected]

Item adicionado ao carrinho

Swiss Vitalis · International Patients Information

Swiss Vitalis.
U.S.-made CBD,
for international
patients.

Hemp-derived CBD,
manufactured in
the United States.

About our products

How international patients
access our products.

How international patients access our products

ANVISA reference listing

Regulatory and
legal notes.

Regulatory and legal notes

Contact Information

Important Disclaimer

País/Região

Idioma

Swiss Vitalis · International Patients Information

Swiss Vitalis. U.S.-made CBD, for international patients.

Hemp-derived CBD,manufactured inthe United States.

About our products

How international patientsaccess our products.

How international patients access our products

ANVISA reference listing

Regulatory andlegal notes.

Regulatory and legal notes

Contact Information

Important Disclaimer

Swiss Vitalis.
U.S.-made CBD,
for international
patients.

Hemp-derived CBD,
manufactured in
the United States.

How international patients
access our products.

Regulatory and
legal notes.